Shumway Capital

Shumway Capital is an investment firm that uses a unique growth-focused investment model. As entrepreneurs themselves, the investment team has first-hand knowledge of how to help other companies accelerate their growth and realize their specific visions. The firm’s partners invest their own capital and provide a permanent capital base for their investments. They focus on high-growth businesses across a wealth of industries and have a collaborative approach that enables the management team and the company to continue operating their business effectively without any disruption.

Chris Lange

Managing Director, Senior Partner and Head of Investments

Kenneth Palumbo

CFO

Chris Shumway

Founder and Managing Partner

11 past transactions

Elligo Health Research

Series E in 2021
Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies. Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas.

Vedanta Biosciences

Series D in 2021
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.

Finch Therapeutics

Series D in 2020
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Finch Therapeutics

Series C in 2019
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Vedanta Biosciences

Series C in 2019
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.

Elligo Health Research

Series C in 2019
Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies. Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas.

Elligo Health Research

Series B in 2018
Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies. Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas.

Finch Therapeutics

Series B in 2018
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Artsy

Series D in 2017
Artsy is the world’s largest online art marketplace. Browse over 1 million artworks by iconic and emerging artists from 4000+ galleries and top auction houses.

Elligo Health Research

Series A in 2016
Elligo Health Research is a healthcare company that revolutionizes the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere. It brings clinical research to physician practices, accelerating the development of pharmaceutical, biotechnology, and medical device products and therapies. Elligo Health Research was founded in 2016 and is headquartered in Austin, Texas.

Trumid

Series A in 2015
Trumid is a financial technology company building a trading network. The company optimizes the credit trading experience by combining agile technology and market expertise, with a focus on product design.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.